FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148903359> ?p ?o ?g. }

• W2148903359 endingPage "475.e6" @default.
• W2148903359 startingPage "468" @default.
• W2148903359 abstract "BackgroundAlthough peanut oral immunotherapy (OIT) has been conclusively shown to cause desensitization, it is currently unknown whether clinical protection persists after stopping therapy.ObjectiveOur primary objective was to determine whether peanut OIT can induce sustained unresponsiveness after withdrawal of OIT.MethodsWe conducted a pilot clinical trial of peanut OIT at 2 US centers. Subjects age 1 to 16 years were recruited and treated for up to 5 years with peanut OIT. The protocol was modified over time to permit dose increases to a maximum of 4000 mg/d peanut protein. Blood was collected at multiple time points. Clinical end points were measured with 5000-mg double-blinded, placebo-controlled food challenges once specific criteria were met.ResultsOf the 39 subjects originally enrolled, 24 completed the protocol and had evaluable outcomes. Twelve (50%) of 24 successfully passed a challenge 1 month after stopping OIT and achieved sustained unresponsiveness. Peanut was added to the diet. At baseline and the time of challenge, such subjects had smaller skin test results, as well as lower IgE levels specific for peanut, Ara h 1, and Ara h 2 and lower ratios of peanut-specific IgE/total IgE compared with subjects not passing. There were no differences in peanut IgG4 levels or functional activity at the end of the study.ConclusionsThis is the first demonstration of sustained unresponsiveness after peanut OIT, occurring in half of subjects treated for up to 5 years. OIT favorably modified the peanut-specific immune response in all subjects completing the protocol. Smaller skin test results and lower allergen-specific IgE levels were predictive of successful outcome. Although peanut oral immunotherapy (OIT) has been conclusively shown to cause desensitization, it is currently unknown whether clinical protection persists after stopping therapy. Our primary objective was to determine whether peanut OIT can induce sustained unresponsiveness after withdrawal of OIT. We conducted a pilot clinical trial of peanut OIT at 2 US centers. Subjects age 1 to 16 years were recruited and treated for up to 5 years with peanut OIT. The protocol was modified over time to permit dose increases to a maximum of 4000 mg/d peanut protein. Blood was collected at multiple time points. Clinical end points were measured with 5000-mg double-blinded, placebo-controlled food challenges once specific criteria were met. Of the 39 subjects originally enrolled, 24 completed the protocol and had evaluable outcomes. Twelve (50%) of 24 successfully passed a challenge 1 month after stopping OIT and achieved sustained unresponsiveness. Peanut was added to the diet. At baseline and the time of challenge, such subjects had smaller skin test results, as well as lower IgE levels specific for peanut, Ara h 1, and Ara h 2 and lower ratios of peanut-specific IgE/total IgE compared with subjects not passing. There were no differences in peanut IgG4 levels or functional activity at the end of the study. This is the first demonstration of sustained unresponsiveness after peanut OIT, occurring in half of subjects treated for up to 5 years. OIT favorably modified the peanut-specific immune response in all subjects completing the protocol. Smaller skin test results and lower allergen-specific IgE levels were predictive of successful outcome." @default.
• W2148903359 created "2016-06-24" @default.
• W2148903359 creator A5007418772 @default.
• W2148903359 creator A5008852386 @default.
• W2148903359 creator A5034220226 @default.
• W2148903359 creator A5034568062 @default.
• W2148903359 creator A5040909413 @default.
• W2148903359 creator A5043192106 @default.
• W2148903359 creator A5048531900 @default.
• W2148903359 creator A5061903827 @default.
• W2148903359 creator A5062901617 @default.
• W2148903359 creator A5063862530 @default.
• W2148903359 creator A5067219107 @default.
• W2148903359 creator A5069066471 @default.
• W2148903359 creator A5071234496 @default.
• W2148903359 creator A5073813153 @default.
• W2148903359 creator A5075200115 @default.
• W2148903359 creator A5076518194 @default.
• W2148903359 creator A5079505084 @default.
• W2148903359 creator A5085949410 @default.
• W2148903359 creator A5086785046 @default.
• W2148903359 date "2014-02-01" @default.
• W2148903359 modified "2023-10-10" @default.
• W2148903359 title "Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy" @default.
• W2148903359 cites W1792045011 @default.
• W2148903359 cites W1963754158 @default.
• W2148903359 cites W1977800771 @default.
• W2148903359 cites W1978348694 @default.
• W2148903359 cites W1983739223 @default.
• W2148903359 cites W1994095603 @default.
• W2148903359 cites W1996097906 @default.
• W2148903359 cites W2000815418 @default.
• W2148903359 cites W2000826674 @default.
• W2148903359 cites W2012513978 @default.
• W2148903359 cites W2022380219 @default.
• W2148903359 cites W2022764839 @default.
• W2148903359 cites W2026817756 @default.
• W2148903359 cites W2028803867 @default.
• W2148903359 cites W2037121276 @default.
• W2148903359 cites W2041899741 @default.
• W2148903359 cites W2045336002 @default.
• W2148903359 cites W2046574729 @default.
• W2148903359 cites W2057706989 @default.
• W2148903359 cites W2070541733 @default.
• W2148903359 cites W2079909497 @default.
• W2148903359 cites W2101419854 @default.
• W2148903359 cites W2122828585 @default.
• W2148903359 cites W2132083799 @default.
• W2148903359 cites W2148664250 @default.
• W2148903359 cites W2153592178 @default.
• W2148903359 cites W2162344297 @default.
• W2148903359 cites W2162557336 @default.
• W2148903359 cites W2162744119 @default.
• W2148903359 cites W2312829609 @default.
• W2148903359 doi "https://doi.org/10.1016/j.jaci.2013.11.007" @default.
• W2148903359 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3960331" @default.
• W2148903359 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24361082" @default.
• W2148903359 hasPublicationYear "2014" @default.
• W2148903359 type Work @default.
• W2148903359 sameAs 2148903359 @default.
• W2148903359 citedByCount "349" @default.
• W2148903359 countsByYear W21489033592012 @default.
• W2148903359 countsByYear W21489033592014 @default.
• W2148903359 countsByYear W21489033592015 @default.
• W2148903359 countsByYear W21489033592016 @default.
• W2148903359 countsByYear W21489033592017 @default.
• W2148903359 countsByYear W21489033592018 @default.
• W2148903359 countsByYear W21489033592019 @default.
• W2148903359 countsByYear W21489033592020 @default.
• W2148903359 countsByYear W21489033592021 @default.
• W2148903359 countsByYear W21489033592022 @default.
• W2148903359 countsByYear W21489033592023 @default.
• W2148903359 crossrefType "journal-article" @default.
• W2148903359 hasAuthorship W2148903359A5007418772 @default.
• W2148903359 hasAuthorship W2148903359A5008852386 @default.
• W2148903359 hasAuthorship W2148903359A5034220226 @default.
• W2148903359 hasAuthorship W2148903359A5034568062 @default.
• W2148903359 hasAuthorship W2148903359A5040909413 @default.
• W2148903359 hasAuthorship W2148903359A5043192106 @default.
• W2148903359 hasAuthorship W2148903359A5048531900 @default.
• W2148903359 hasAuthorship W2148903359A5061903827 @default.
• W2148903359 hasAuthorship W2148903359A5062901617 @default.
• W2148903359 hasAuthorship W2148903359A5063862530 @default.
• W2148903359 hasAuthorship W2148903359A5067219107 @default.
• W2148903359 hasAuthorship W2148903359A5069066471 @default.
• W2148903359 hasAuthorship W2148903359A5071234496 @default.
• W2148903359 hasAuthorship W2148903359A5073813153 @default.
• W2148903359 hasAuthorship W2148903359A5075200115 @default.
• W2148903359 hasAuthorship W2148903359A5076518194 @default.
• W2148903359 hasAuthorship W2148903359A5079505084 @default.
• W2148903359 hasAuthorship W2148903359A5085949410 @default.
• W2148903359 hasAuthorship W2148903359A5086785046 @default.
• W2148903359 hasBestOaLocation W21489033591 @default.
• W2148903359 hasConcept C126322002 @default.
• W2148903359 hasConcept C141105273 @default.
• W2148903359 hasConcept C142724271 @default.
• W2148903359 hasConcept C159654299 @default.
• W2148903359 hasConcept C170493617 @default.

• next